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ABSTRACT
Some tropical diseases are the direct cause of severe disturbances of cerebral function while others affect 
only finer cerebral systems controlling fears, anxiety and personality traits. The mechanisms by which 
psychiatric symptoms are produced in tropical disorders are not any different from the mechanisms that 
relate to any physical disorders. Neuropsychiatric symptoms may be caused by a number of different me-
chanisms including bacterial toxins, release of cytokines, hyperthermia, shock (poor perfusion), acute renal 
insufficiency, pulmonary failure (shock lung), coagulopathy, disruption of the blood-brain barrier, and/or the 
nest of pathogens into the central nervous system. The following tropical illnesses can be associated with 
neuropsychiatric symptoms: neurocysticercosis, malaria, trypanosomiasis, dengue, and schistosomiasis. 
Neurological and psychiatric impairments induced by tropical diseases both represent a major category of 
invalidating disorders, which cause profound changes in the nervous system functions, often associated 
with severe sequels or late-onset disturbances. It is therefore important to disseminate knowledge of the 
neuropsychiatric symptoms accompanying tropical diseases in order to increase the awareness of these 
problems and challenges.
(Int Marit Health 2015; 66, 1: 30–35)
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INTRODUCTION
Psychiatric symptoms can occur as a part of clinical 
manifestations of several systemic and central nervous 
system (CNS) infections. Some tropical diseases are the 
direct cause of severe disturbances of cerebral function 
while others affect only finer cerebral systems controlling 
fears, anxiety and personality traits [1]. The study on fe-
brile onset of psychiatric disorders has shown that at least 
a third of patients developed variety of symptoms including 
excitement, aggressive behaviour, sleep disturbance, visual 
and auditory hallucinations, delusions, disorganised think-
ing and disorientation, depression, mutism, and catatonia 
[2]. The mechanisms by which psychiatric symptoms are 
produced in tropical illnesses are not any different from 
the mechanisms that relate to any physical disorders. Neu-
ropsychiatric symptoms may be triggered by a number of 
different mechanisms including bacterial toxins, release of 
cytokines, hyperthermia, shock (poor perfusion), acute renal 
insufficiency, pulmonary failure (shock lung), coagulopathy, 
disruption of the blood-brain barrier, and/or spread of path-
ogens into the CNS. An acute change in mental status may 
be the first sign of infection. Psychiatric disorders related 
to brain damage or dysfunction are particularly common, 
reflecting pre-existing deprivations and the occurrence of 
multiple pathological conditions. Experience suggested 
that the following tropical illnesses are frequently associ-
ated with neuropsychiatric symptoms: neurocysticercosis, 
malaria, trypanosomiasis, dengue, and schistosomiasis.
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TROPICAL DISEASES WITH  
NEUROPSYCHIATRIC MANIFESTATIONS
NEUROCYSTICERCOSIS
Neurocysticercosis (NCC) is the parasitic infection of 
the CNS, the most common human neuroparasitosis. NCC 
is mainly located in grey matter or at the junction of grey 
and white matter with a rich blood supply. The clinical man-
ifestations of NCC are varied and depend on the topogra-
phy, number, the size and stage of lesions, as well as the 
status of the host’s immune response to the parasite [3]. 
The initial immune response to the cysticerci is minimal, 
which explains a long latent period. The most common 
manifestation of NCC include seizures, headache, intrac-
ranial hypertension due to blockage of cerebrospinal fluid 
(CSF) flow, stroke, ophthalmologic and endocrinological 
manifestations [4]. In intraparenchymal NCC, seizure is 
the most common clinical manifestation, while in extra-
parenchymal NCC (refers to infections of the ventricles 
and subarachnoid spaces) manifestations are associated 
with hydrocephalus, multiple cranial nerves dysfunction, 
visual and hormonal impairment (due to compression of 
the hypophyseal stem and optic nerves) [4–6]. Headache 
and signs of intracranial pressure are more common in 
the extraparenchymal (88%) in comparison with the paren-
chymal location (10%) [7]. Neurocysticercosis can cause 
almost any neurological symptoms, but late-onset epilepsy 
and intracranial hypertension are its most common clinical 
manifestations [4]. Cognitive and behavioural deteriorations 
in NCC are more commonly associated with hydrocephalus 
or multiple lesions [4, 6]. Severity of psychiatric symptoms 
may correlate with treatment of NCC with anti-parasitic 
drugs, associated with an increase in CNS inflammation [8]. 
Among mental changes the most commonly reported ones 
are confusion, disorientation, memory loss, hallucinations, 
psychomotor incoordination, progressive deterioration of 
language ability and mental deterioration [9]. Psychiatric 
disorders were observed in 65.8% of people, while cognitive 
decline was observed in 87.5% of patients with NCC. As 
for psychiatric disorders/illnesses, depressive disorders 
and psychosis were seen in 52.6% and 14.2% of cases, 
respectively [8]. In other study schizophrenic and manic-like 
episodes were reported as possible initial signs of NCC [10]. 
Disease progression and intracranial hypertension correlate 
with higher levels of psychiatric co-morbidity. It has been 
suggested [10] that psychiatric symptoms associated with 
NCC were not due to the direct effect of the parasite on 
particular brain tissue but were rather related to mechani-
cal alternation in CSF pressure and inflammatory injury of 
the brain parenchyma. A study carried out to compare the 
clinical manifestation between paediatric and NCC patients 
[11] reported that seizures were more common in children 
(89.4% vs. 56.1%), intracranial hypertension and headaches 
were more frequent in adults (27.2% vs. 15.2%, and 35.1% 
vs. 21.7%, respectively), and focal deficits were present in 
17% of adults and 12% of children. Dementia can be an 
important presenting symptom of NCC which is reported in 
about one-fifth of the patients [12]. Compared to degen-
erative dementia (the elderly is the main group affected), 
dementia related to NCC can be seen in any age group. 
Sometimes dementia might also co-manifest with other 
neuropsychiatric symptoms (seizure, hallucination) [13]. 
Dementia syndrome observed in patients with NCC could 
result from a combined effect of multiple parasitic and 
vascular lesions, disrupting fronto-parieto-temporal net-
works related to the intellectual functioning in patients with 
vulnerable brains (because of repeated epileptic seizures, 
low educational level and advanced age) [14]. 
It has been proposed [15] that NCC should be classified 
into three groups according to neuropsychiatric manifes-
tations as acute (parenchymatous or subarachnoid cystic 
infiltration), chronic (chronic meningitis, obstructive hydro-
cephalus, progressive dementia) and sequelae (epilepsy 
with or without headache). 
MALARIA
Malaria is a disease caused by Plasmodium spp. that 
in its cerebral form may lead to acute or long-term neuro-
logical deficits, even with an effective antimalarial therapy, 
causing vascular obstruction, reduced cerebral blood flow 
and other changes [16]. Clinical features of severe malaria 
include cerebral malaria (CM), with impaired consciousness 
(including coma), prostration, multiple convulsions, deep 
breathing and respiratory distress (metabolic acidosis), 
acute pulmonary oedema and acute respiratory distress syn-
drome, circulatory collapse or shock and acute kidney injury 
[17, 18]. According to the time of the symptom onset, CM 
may be classified into two patterns of neuropsychological 
sequelae [19]. The first one is immediate and characterised 
by coma and status epilepticus during the acute illness, 
resulting in focal sequelae such as hemiplegia and focal 
seizures, or multifocal sequelae with spastic quadriparesis, 
motor disorders, cognitive and behavioural impairment, 
blindness, speech or hearing impairment. The second pat-
tern (post-malaria neurological syndrome) develops within 
months or years after CM, and behavioural deficits and/or 
epilepsy may occur. Malarial infection can be also associ-
ated with a wide range of neuropsychiatric symptoms [20]. 
Clinically, this picture may present with disorientation, mild 
stupor or even psychosis. However, it rapidly progresses to 
seizures and coma with decerebrate posture. Occasionally, 
frankly psychotic behaviour can be the first manifestation 
of cerebral involvement during malarial infection. Paranoid 
psychosis, mania, hallucinations, and delusions were the 
Int Marit Health 2015; 66, 1: 30–35
www.intmarhealth.pl32
commonest neuropsychiatric complications in some cases. 
Other, neurological presentations include hemiplegia, cer-
ebral palsy, rare cases of Gullain-Barre syndrome, cerebel-
lar ataxia, extra-pyramidal symptoms, trismus, peripheral 
neuropathy, isolated 6th nerve palsy, and foot drop. Ocular 
bobbing, nystagmus, sudden blindness due to vitreous 
haemorrhage, subarachnoid haemorrhage due to dissem-
inated intravascular coagulation, myelitedes-resembling 
amyotrophic lateral sclerosis, tabesdorsalis-like syndrome, 
and combined disseminated encephalomyelitis have also 
been observed [21, 22]. Neuropsychiatric impairments due 
to CM in children include: long-term cognitive impairment, 
acquired language disorder, inattention, impulsiveness and 
hyperactivity, conduct disorders, impaired social develop-
ment. and obsessive symptoms. Self-injurious and destruc-
tive behaviours have also been observed [23].
The pathological mechanisms that lead to neurological 
complications and mortality have not yet been clearly de-
fined. It is believed that in the infected erythrocytes, plate-
lets and activated leukocytes inflammatory events occur 
owing to increased levels of adhesion molecules on the 
inflamed endothelium, leading to a reduction in microvas-
cular blood flow, decreased delivery of nutrients to affected 
brain tissue and vessel walls, followed by haemorrhage 
and neuronal alternations [16, 24–26]. The disturbances 
in the homeostasis of the cerebral microcirculation play 
an important role in the pathogenesis of CM, generating 
vascular obstructions, reduced cerebral blood flow and 
blood-brain barrier disruption associated with high cerebral 
vasoconstriction that in the presence of seizures and/or 
fever increases metabolic demands with consequent risk 
of neural injury [16, 27–29]. 
Post-malaria neurological syndrome occurs after symp-
tomatic malarial infection and clearance of parasites from 
blood. It is characterised by the development of neurologi-
cal and psychiatric symptoms that can occur 1–4 months 
after exposure. Clinical manifestations include generalised 
convulsion, delayed cerebellar ataxia, inappropriate speech 
or behaviour, aggressiveness, psychosis with visual or/and 
auditory hallucinations, catatonia with waxy flexibility, fine 
postural tremor, and decreased muscle tone [17, 22]. Hy-
peractivity, impulsiveness and inattentiveness have also 
been observed in CM survivors [19], similar to what occurs 
in attention deficit hyperactivity disorder (ADHD), which 
produces impairments in the cognitive, behavioural, and in-
terpersonal domains. Most probably, damage occasioned by 
CM in the frontostriatal and cerebellar areas by a decrease 
in local blood flow or neuronal loss produces impairments in 
dopamine signalling and consequently ADHD [30]. The syn-
drome usually occurs in patients originally treated for severe 
malaria and is strongly correlated with mefloquine treatment 
[31]. In about 28% of patients with P. falciparum malaria 
who were treated with mefloquine neuropsychiatric adverse 
reactions developed [32]. The quinoline antimalarial drugs 
are all known for their neuropsychiatric adverse effects while 
artemisinin or antifolates are not known to be associated 
with neuropsychiatric complications [31]. Neuropsychiatric 
adverse effects of mefloquine include anxiety, paranoia, de-
pression, hallucinations, psychotic behaviour and possibly 
suicide. Mefloquine-induced psychosis can be preceded by 
a prodromal phase of moderate symptoms such as dizziness, 
insomnia, and generalised anxiety followed by frank psy-
chosis with psychomotor agitation and paranoid delusions 
[33]. Chloroquine treatment can rarely be associated with 
neuropsychiatric symptoms such as increased psychomotor 
activity, disorientation, incoherent speech, confusion and 
outbursts of abnormal behaviour [34]. Chloroquine treat-
ment following an experimental malarial infection caused 
serious psychiatric symptoms in a volunteered participant 
including symptoms of depersonalisation, anxiety, vivid 
unpleasant dreams, headache, photophobia and paranoid 
delusions which persisted for over 4 months [31].
TRYPANOSOMIASIS
The family of protozoa Trypanosomatidae causes two 
clinically different syndromes, African trypanosomiasis 
(AT, sleeping sickness) and American trypanosomiasis 
(Chagas disease). 
There are two recognised stages in the clinical presenta-
tion of AT, namely the early (haemolymphatic) stage, and 
the late encephalitic stage when the CNS is involved. The 
disease onset can be acute (CNS invasion by the parasite 
occurs early), within a few months after an initial infection, 
but also slower, with chronic symptoms and late CNS infec-
tion lasting from months to years. An early (haemolymphatic) 
stage of the disease is variable but usually occurs 1–3 
weeks after the bite. Episodes of fever lasting 1–7 days 
occur together with generalised lymphadenopathy. The 
early stage symptoms tend to be non-specific and include: 
malaise, headache, arthralgia, generalised weakness, and 
weight loss [35]. Subsequently multiple organs and systems 
may be infected [36], including the spleen, liver, skin, car-
diovascular system, endocrine system, and the eyes. In the 
late (encephalitic) stage of the disease the first occurrence 
is insidious and the potential clinical phenotype is wide [36]. 
Due to broad neurologic spectrum reported symptoms can 
be grouped into general categories such as psychiatric, 
motor, and sensory abnormalities, and sleep disturbances. 
Mental disturbances may be subtle, and include irritability, 
lassitude, headache, apparent personality changes, and 
overt psychiatric presentations such as violence, halluci-
nations, suicidal tendencies, and mania [36]. Motor sys-
tem involvement may include limb tremors, tongue and 
limb muscle fasciculation, limb hypertonia and pyramidal 
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weakness, choreiform and athetoid movements, dysar-
thria, cerebellar ataxia, and polyneuritis [36]. Sensory 
involvement may manifest as painful hyperaesthesia, 
pruritus, and also deep hyperaesthesia. The character-
istic sleep disturbances include lassitude, distractibility, 
and spontaneous, uncontrollable urges to sleep, along 
with a reversal of the normal sleep-wake cycle in which 
daytime somnolence alternates with nocturnal insom-
nia. While these various features, including the sleep 
abnormalities, are typical of AT, they are not individually 
diagnostic, since some of them may also be seen during 
other CNS infections. If untreated, the patient progresses 
to the final stage of the disease, which is characterised by 
seizures, severe somnolence, double incontinence, cere-
bral oedema, coma, systemic organ failure, and inevitable 
death. Reactivated disease with CNS involvement occurs 
in leukaemia, lymphoma, Hodgkin’s disease, transplan-
tation, and AIDS [37].
Chagas disease is the most severe parasitic infection 
of the heart [38]. Chagas disease occurs in two phases: 
acute and chronic. Initial infection at the site of parasite 
entry is characterised by the presence of infective trypo-
mastigotes in leukocytes and cells of subcutaneous tissues, 
and by the development of interstitial oedema, lymphocyt-
ic infiltration, and reactive hyperplasia of adjacent lymph 
nodes. After dissemination through the lymphatic system 
and the bloodstream, parasites concentrate mainly in the 
muscles (including the myocardium) and ganglion cells. 
The CNS is considered an immunoprivileged site [39] into 
which the entrance of macromolecules and immune cells 
is restricted [38]. Although cerebrovascular complications 
in patients with Chagas disease have not been reported, 
the post mortem studies have shown that roughly 9% to 
36% of patients with chronic Chagas cardiomyopathy show 
evidence of cerebral infarctions [40]. In most patients with 
the symptomatic acute form of the disease, all clinical 
manifestations, including neurological signs and symptoms, 
disappear spontaneously without apparent delayed effects 
[41]. It is possible that the nervous form of the disease can 
be attributed to delayed effects on the CNS that result from 
acute lesions or parasite persistence. The neurocognitive 
impairments observed in Chagas disease might be due 
to the immune response that develops within the CNS 
microenvironment; alternatively, they could be an indirect 
result of a more general systemic immune response [42].
DENGUE
Dengue fever, also known as break bone fever, is 
a vector-borne infection that causes a severe flu-like illness. 
Dengue can vary from mild to severe — dengue shock syn-
drome and dengue haemorrhagic fever. CNS manifestations 
classically associated with dengue infection are headache, 
dizziness, sleeplessness, somnolence, restlessness, mental 
irritability, depression; altered sensorium such as lethargy, 
confusion, and coma. Seizures, neck stiffness and paresis 
are less common. CNS manifestations may develop before 
or after haemorrhagic manifestations [43]. Many factors 
may be considered to be directly or indirectly associated with 
CNS signs and symptoms in dengue haemorrhagic fever, 
the main pathology being leakage of plasma into serous 
spaces and abnormal haemostasis leading to hypovolemic 
shock and haemorrhage in many organs of the body. Acute 
liver failure is considered to be another factor causing CNS 
manifestations. The causes of these manifestations are 
multifactorial but most are commonly found to be associ-
ated with prolonged shock, metabolic acidosis and severe 
disseminated intravascular coagulopathy which could result 
in both hepatic and brain dysfunction [43]. Among the psy-
chiatric symptoms occurring in patients with dengue manic 
symptoms have been reported: excessive talkativeness, 
joyfulness, increased activity, increased self-confidence, 
decreased need for sleep and food, irritability, outbursts 
of aggression [44]. Post-infectious sequelae are mainly 
amnesia, dementia, manic psychosis, Reye’s syndrome and 
meningoencephalitis [45].
SCHISTOSOMIASIS
Schistosomiasis is a parasite infection caused by Schis-
tosoma spp. (trematodes), blood flukes which can lead in 
people to protein energy malnutrition as a result of damage 
of tissues and blood loss. Another consequences of infec-
tion are iron deficiency anaemia [46], impaired cognitive 
performance and development [47]. Psychiatric symptoms 
may occur in two settings. One is acute toxaemic schisto-
somiasis in previously unexposed people. The symptoms 
like headache, malaise, and muscle aches usually occur 
several weeks after exposure. These symptoms dramati-
cally progress several weeks later when trematodes begin 
to lay eggs. The clinical picture is one of toxaemia which 
is associated with encephalopathy. The other psychiatric 
presentation may occur in a chronically infected individual. 
Migration of the eggs to the CNS can induce granulomatous 
reaction, leading to symptoms of increased intracranial 
pressure (e.g., headache, visual changes, nausea, and pap-
illoedema). Focal neurological symptoms may occur as well.
CONCLUSIONS
Tropical diseases are most prevalent in countries lo-
cated in hot climate regions. They are less common in 
temperate climate where vectors are reduced due to winter 
and low temperatures. However, intense migration and 
the opportunity to travel to tropical regions have led to an 
increased incidence of this kind of diseases globally. The 
nervous system involvement in neglected tropical diseases 
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and conditions is a disregarded field of investigation. Neuro-
psychiatric syndromes are often associated with these types 
of infections. Additionally, drugs commonly used to treat tropi-
cal illnesses may impair mood and cause anxiety, agitation or 
psychosis. Emotional states may in turn affect the experience 
of medical illness. Neurological and psychiatric impairments 
induced by tropical diseases both represent a major category 
of invalidating disorders, which cause profound changes in 
the nervous system functions, often associated with severe 
sequels or late-onset disturbances. It is therefore important 
to disseminate knowledge of the neuropsychiatric symptoms 
accompanying tropical diseases to increase the awareness 
of these problems and challenges.
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